Amphera – a company developing MesoPher cell therapy to treat cancer – has delivered positive results from its phase 2 Reactive trial and phase 2/3 DENIM trial.
During the phase 2 Reactive study, patients with resected pancreatic cancer who had completed standard-of-care chemotherapy received three bi-weekly injections of Amphera’s MesoPher dendritic cell therapy along with booster injections at four- and seven-month intervals.
The research met the primary endpoint with efficacy and safety data from two cohorts across a study of 38 patients. This demonstrated a statistically significant two-year recurrence free survival of 60% as well as an excellent safety.
